Immunotherapy

 

The immune system is a system of cells and organs whose function is to defend an organism from foreign pathogens. With the ability to mount a response against virtually any foreign material and return to a quiescent state following neutralization of the threat, this fascinating organ system displays remarkable specificity and plasticity. To achieve this, there is a multifaceted balancing act between the many activators and suppressors that maintains homeostasis of perhaps the body’s most complex organ system.

Activation of the immune system involves a number of checkpoints in order to ensure proper activation. For instance, T cell activation requires binding of the T cell receptor to the MHC antigen, yet this interaction alone is not sufficient for producing a T cell response. Full T cell activation and inactivation requires the coordination of a multitude of co-stimulatory and inhibitory signals. For example, T cell activation can result from the combination of MHC:TCR and B7-1:CD28 interaction. In contrast, B7-1 binding to CTLA4 results in an inhibitory signal that prevents activation.

Given its diverse function and the fact that the immune system plays a role in virtually all human diseases, immunotherapy has become an important approach for the treatment of numerous diseases. Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response. This often involves targeting immunoreceptors, such as those discussed above, with small molecule inhibitors/activators or immune system components, including antibodies or antibody fragments (Fab). Immunotherapies have shown efficacy in the treatment of cancer, autoimmune diseases, inflammatory diseases, and more.

BPS Bioscience offers many purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, we offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

References:

1.  Pardoll, D.M., Nat. Rev. Cancer. 2012; 12: 252-264.
2.  Lesterhuis, W.J., et al., Nat. Rev. Drug. Disc. 2011; 10: 591-600.

Immunotherapy Subcategories

Items 76 to 100 of 430 total

per page
Page:
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6

Catalog#SizeProduct NamePrice
71234 50 μg CD112, His-tag, Biotin-labeled (Human) HiP™
$420
79116 100 μg CD112R, Fc-Fusion, Avi-Tag (Human) HiP™
$310
79270 50 μg CD112R, Fc-Fusion, Avi-Tag, Biotin-Labeled (Human) HiP™
$420
72510 100 μg CD113, Fc-Fusion (IgG1), Avi-Tag
$310
71170 100 µg CD137 (4-1BB), Fc fusion (Human) HiP™
$300
71171 50 µg CD137 (4-1BB), Fc Fusion, Biotin-labeled (Human) HiP™
$405
71250 100 μg CD137, Fc fusion (hIgG1) (Mouse)
$310
71254 100 µg CD137, Fc fusion (mIgG2a), Avi-tag (Mouse) HiP™
$310
71255 50 µg CD137, Fc fusion (mIgG2a), Biotin-labeled (Mouse) HiP™
$420
79289 2 vials CD137/NF-κB Reporter - HEK293 Recombinant Cell Line
$8,000
71189 100 µg CD137L (4-1BB ligand), His-tag
$310
60523 2 vials CD137L (4-1BBL) CHO-K1 Recombinant Cell Line
$5,775
72517 100 µg CD137L, His-Tag (Mouse)
$310
72025 96 reactions CD137[Biotinylated]:CD137L Inhibitor Screening Assay Kit
$995
72307 50 μg CD150, Fc Fusion (IgG1), Biotin Labeled (Human)
$420
72304 100 μg CD150, Fc Fusion, Avi-Tag (Human)
$320
60537 2 vials CD155 (PVR) - HEK293 Recombinant Cell Line
$8,000
71181 100 µg CD155 (PVR), His-tag (Human)
$315
71181-2 1 mg CD155 (PVR), His-tag (Human)
$2,835
71167 100 µg CD155 (PVR), His-tag (Mouse) HiP™
$310
60548 2 vials CD155 / TCR Activator - CHO Recombinant Cell line
$8,000
71168 50 µg CD155, His-tag, Biotin-labeled (Mouse) HiP™
$420
71173 100 µg CD160, His-tag (Human) HiP™
$310
71135 50 µg CD160, His-tag, Biotin-labeled (Human) HiP™
$420
71264 100 μg CD2, Fc fusion, Avi-Tag, (Human) HiP™
$320

Items 76 to 100 of 430 total

per page
Page:
  1. 2
  2. 3
  3. 4
  4. 5
  5. 6